Atossa Therapeutics, Inc.

NasdaqCM:ATOS Stock Report

Market Cap: US$39.2m

Atossa Therapeutics Management

Management criteria checks 2/4

Atossa Therapeutics' CEO is Steve Quay, appointed in Apr 2009, has a tenure of 17.17 years. total yearly compensation is $2.50M, comprised of 29.2% salary and 70.8% bonuses, including company stock and options. directly owns 0.011% of the company’s shares, worth $4.22K. The average tenure of the management team and the board of directors is 1.4 years and 14.3 years respectively.

Key information

Steve Quay

Chief executive officer

US$2.5m

Total compensation

CEO salary percentage29.21%
CEO tenure17.2yrs
CEO ownership0.01%
Management average tenure1.4yrs
Board average tenure14.3yrs

Recent management updates

Recent updates

Analysis Article • Dec 03

Is Atossa Therapeutics (NASDAQ:ATOS) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Jul 15

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Apr 01

Here's Why We're Not Too Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Nov 12

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Nov 08

Atossa Therapeutics: Important News, But The Company Still Has A Long Way To Go

Summary Atossa Therapeutics focuses on developing endoxifen for hormone receptor-positive breast cancer, with promising early-stage trial results but lacks definitive proof of efficacy. The company has strong financials, with $79.5 million in cash and a cash runway of 13-14 quarters, minimizing immediate dilution risk. Despite promising signals, preventive endocrine therapy faces heavy clinical resistance and requires well-powered confirmatory studies to prove its viability. Given the high risk, I maintain a "Sell" rating, anticipating better entry points in the future. Read the full article on Seeking Alpha
Analysis Article • Jul 01

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 07

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Nov 08

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Apr 26

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Jan 09

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...

CEO Compensation Analysis

How has Steve Quay's remuneration changed compared to Atossa Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$38m

Dec 31 2025US$3mUS$731k

-US$35m

Sep 30 2025n/an/a

-US$30m

Jun 30 2025n/an/a

-US$29m

Mar 31 2025n/an/a

-US$26m

Dec 31 2024US$3mUS$706k

-US$26m

Sep 30 2024n/an/a

-US$27m

Jun 30 2024n/an/a

-US$26m

Mar 31 2024n/an/a

-US$30m

Dec 31 2023US$2mUS$706k

-US$30m

Sep 30 2023n/an/a

-US$30m

Jun 30 2023n/an/a

-US$32m

Mar 31 2023n/an/a

-US$28m

Dec 31 2022US$3mUS$706k

-US$27m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$21m

Mar 31 2022n/an/a

-US$22m

Dec 31 2021US$6mUS$659k

-US$21m

Sep 30 2021n/an/a

-US$28m

Jun 30 2021n/an/a

-US$26m

Mar 31 2021n/an/a

-US$23m

Dec 31 2020US$3mUS$601k

-US$22m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020n/an/a

-US$13m

Mar 31 2020n/an/a

-US$16m

Dec 31 2019US$6mUS$601k

-US$17m

Compensation vs Market: Steve's total compensation ($USD2.50M) is above average for companies of similar size in the US market ($USD642.98K).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.

CEO

Steve Quay (75 yo)

17.2yrs
Tenure
US$2,502,856
Compensation

Dr. Steven C. Quay, also known as Steve, M.D., Ph D., FCAP, has been the Chief Executive Officer and President of Atossa Therapeutics, Inc. (formerly known as Atossa Genetics Inc.) since April 30, 2009 and...

Leadership Team

NamePositionTenureCompensationOwnership
Steven Quay
Chairman17.2yrsUS$2.50m0.011%
$ 4.2k
Mark Daniel
Chief Financial Officerless than a yearUS$805.45kno data
Janet Rea
Senior Vice President of Research & Developmentless than a yearno datano data
Delly Behen
Senior Vice President of Business Operations1.4yrsno datano data
Richard Graydon
Interim Chief Medical Officer3.7yrsno datano data
1.4yrs
Average Tenure

Experienced Management: ATOS's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Steven Quay
Chairman17.2yrsUS$2.50m0.011%
$ 4.2k
Richard Steinhart
Independent Director12.3yrsUS$167.56k0%
$ 0
H. Remmel
Independent Director14.3yrsUS$197.41k0.12%
$ 48.6k
Shu-Chih Chen
Director17.2yrsUS$145.06k0.13%
$ 52.2k
Stephen Galli
Independent Director14.9yrsUS$175.06k0.000080%
$ 31.3
Jonathan Finn
Independent Director2.6yrsUS$163.81k0.14%
$ 53.1k
Tessa Cigler
Independent Director2.3yrsUS$155.84k0%
$ 0
14.3yrs
Average Tenure
69yo
Average Age

Experienced Board: ATOS's board of directors are seasoned and experienced ( 14.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/09 04:31
End of Day Share Price 2026/06/09 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Atossa Therapeutics, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Pooya HemamiEdison Investment Research
Emily BodnarH.C. Wainwright & Co.